This is a review of the preclinical efficacy testing of new antituberculosis drug candidates. It describes existing dynamicin vitroandin vivomodels of antituberculosis chemotherapy and their utility in preclinical evaluations of promising new drugs and combination regimens, with an effort to highlight recent developments. Emphasis is given to the integration of quantitative pharmacokinetic/pharmacodynamic analyses and the impact of lesion pathology on drug efficacy. Discussion also includesin vivomodels of chemotherapy of latent tuberculosis infection.
No takes yet. Share an insight, caveat, or question.
Eric L. Nuermberger (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: